Following in Merck's Footsteps: Classic Scientific Books

Last December, the Merck Index celebrated its 100th birthday. The 2,350 pages of the latest edition, the 11th - with 10,000 entries, 8,000 structures, 62,000 synonyms, and 129 pages of charts and tables - seem a far cry from the original 170 pages published in 1889. The first edition, named for the German company (originally a pharmacy) founded in 1668, was written for the physician, chemist, and pharmacist, listing "whatever chemical products are to-day adjudged as being useful in either medi

Written byRicki Lewis
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Last December, the Merck Index celebrated its 100th birthday. The 2,350 pages of the latest edition, the 11th - with 10,000 entries, 8,000 structures, 62,000 synonyms, and 129 pages of charts and

tables - seem a far cry from the original 170 pages published in 1889. The first edition, named for the German company (originally a pharmacy) founded in 1668, was written for the physician, chemist, and pharmacist, listing "whatever chemical products are to-day adjudged as being useful in either medicine or technology."

The major selling point of the index - a wealth of information provided conveniently in one volume - hasn't changed. But the new Merck Index (S. Budavari et al., eds., Rahway, N.J., Merck & Co., 1989) serves a far broader audience than did the first edition, reflecting the overlap of biology, chemistry, and medicine, as well as interest from others, such as journalists, investors, and patent attorneys. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies